The New England Journal of Medicine recently published Phase 1/2 clinical data from the RMC-6236-001 trial evaluating daraxonrasib (RASONQUE), an oral RAS(ON) multi-selective inhibitor, in patients with previously treated advanced RAS-mutant non-small cell lung cancer (NSCLC) harboring mutations other than RAS G12C. In a prespecified subgroup of 38 docetaxel-naïve patients treated at doses of 160 […]
Ivonescimab improved overall survival versus pembrolizumab in PD-L1-positive advanced NSCLC in the HARMONi-2 trial.
A planned interim analysis of the global, Phase 3 REZILIENT3 trial has demonstrated that zipalertinib (CLN-081/TAS6417) combined with platinum-based chemotherapy achieved a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone as first-line treatment for patients with EGFR exon 20 insertion (ex20ins)–mutant advanced or metastatic non-squamous NSCLC. Based on these […]
SAFFRON Phase III results show that osimertinib plus savolitinib significantly improves progression-free and overall survival in MET-driven EGFR-mutated NSCLC after osimertinib progression, supporting MET testing and a potential new targeted standard of care.
Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab significantly improved progression-free survival in the Phase III OptiTROP-Lung06 trial, becoming the first ADC–immune checkpoint inhibitor combination to meet its primary endpoint in first-line PD-L1–negative NSCLC.
Phase III Krascendo 1 results show divarasib significantly improved progression-free and overall survival versus sotorasib or adagrasib in previously treated KRAS G12C-mutant NSCLC, marking the first head-to-head superiority trial in this patient population.
The phase III LIBRETTO-432 trial demonstrated that adjuvant treatment with the selective RET inhibitor selpercatinib significantly reduced the risk of disease recurrence, progression, or death among patients with resected stage IB to IIIA RET fusion–positive non–small cell lung cancer (NSCLC). Results presented at the 2026 ASCO Annual Meeting showed an approximately 83% reduction in the […]
Ivonescimab, the first PD-1/VEGF bispecific antibody, demonstrated improved overall survival outcomes in previously untreated squamous non-small cell lung cancer (NSCLC) patients, delivering what investigators are calling a landmark advancement for this challenging patient population at the ASCO 2026 Plenary Session. Clinical Takeaway The HARMONi-6 trial represents a pivotal moment in squamous NSCLC treatment, with ivonescimab […]